Susquehanna International Group, LLP Arrowhead Pharmaceuticals, Inc. Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

A detailed history of Susquehanna International Group, LLP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 287,282 shares of ARWR stock, worth $5.33 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

287,282

Previous 102,896 179.2%

Holding current value

$5.33 Million

Previous $2.67 Million 107.97%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.36 - $29.54 $3.57 Million - $5.45 Million	184,386 Added 179.2%	287,282 $5.56 Million
Q2 2024 Aug 15, 2024	SELL	$21.87 - $28.24 $5.61 Million - $7.25 Million	-256,574 Reduced 71.38%	102,896 $2.67 Million
Q1 2024 May 07, 2024	BUY	$27.21 - $39.48 $7.5 Million - $10.9 Million	275,677 Added 329.0%	359,470 $10.3 Million
Q4 2023 Feb 14, 2024	SELL	$21.2 - $31.03 $5.22 Million - $7.63 Million	-246,045 Reduced 74.6%	83,793 $2.56 Million
Q3 2023 Nov 14, 2023	SELL	$26.2 - $36.08 $282,436 - $388,942	-10,780 Reduced 3.16%	329,838 $8.86 Million
Q2 2023 Aug 11, 2023	SELL	$25.16 - $41.38 $2.59 Million - $4.26 Million	-103,066 Reduced 23.23%	340,618 $12.1 Million
Q1 2023 May 16, 2023	BUY	$23.68 - $38.51 $8.51 Million - $13.8 Million	359,519 Added 427.16%	443,684 $11.3 Million
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $3.38 Million - $4.9 Million	-120,701 Reduced 58.92%	84,165 $3.41 Million
Q3 2022 Nov 14, 2022	BUY	$29.63 - $48.31 $1.99 Million - $3.25 Million	67,183 Added 48.8%	204,866 $6.77 Million
Q2 2022 Aug 15, 2022	SELL	$27.79 - $50.61 $1.71 Million - $3.11 Million	-61,435 Reduced 30.85%	137,683 $4.85 Million
Q1 2022 May 16, 2022	BUY	$39.62 - $69.97 $2.72 Million - $4.81 Million	68,699 Added 52.68%	199,118 $9.16 Million
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $2.73 Million - $3.88 Million	-47,073 Reduced 26.52%	130,419 $8.65 Million
Q3 2021 Nov 15, 2021	BUY	$58.38 - $84.96 $879,202 - $1.28 Million	15,060 Added 9.27%	177,492 $11.1 Million
Q2 2021 Aug 11, 2021	SELL	$62.15 - $90.32 $1.8 Million - $2.62 Million	-29,016 Reduced 15.16%	162,432 $13.5 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $5.1 Million - $7.52 Million	-83,138 Reduced 30.28%	191,448 $12.7 Million
Q4 2020 Feb 16, 2021	SELL	$43.82 - $85.37 $1.82 Million - $3.55 Million	-41,598 Reduced 13.16%	274,586 $21.1 Million
Q3 2020 Nov 16, 2020	SELL	$33.21 - $51.27 $4.35 Million - $6.71 Million	-130,914 Reduced 29.28%	316,184 $13.6 Million
Q2 2020 Aug 14, 2020	SELL	$26.12 - $43.27 $102,181 - $169,272	-3,912 Reduced 0.87%	447,098 $19.3 Million
Q1 2020 May 15, 2020	BUY	$20.56 - $63.12 $2.94 Million - $9.02 Million	142,928 Added 46.39%	451,010 $13 Million
Q4 2019 Feb 14, 2020	SELL	$28.14 - $73.01 $873,775 - $2.27 Million	-31,051 Reduced 9.16%	308,082 $19.5 Million
Q3 2019 Nov 14, 2019	BUY	$26.26 - $34.86 $989,109 - $1.31 Million	37,666 Added 12.49%	339,133 $9.56 Million
Q2 2019 Aug 16, 2019	BUY	$17.43 - $28.82 $4 Million - $6.62 Million	229,529 Added 319.07%	301,467 $7.99 Million
Q1 2019 May 15, 2019	SELL	$12.05 - $20.18 $1.16 Million - $1.94 Million	-95,906 Reduced 57.14%	71,938 $1.32 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $818,613 - $1.5 Million	-76,221 Reduced 31.23%	167,844 $2.09 Million
Q1 2018 May 15, 2018	BUY	$3.72 - $7.64 $324,819 - $667,101	87,317 Added 55.71%	244,065 $1.76 Million
Q4 2017 Feb 14, 2018	BUY	$3.14 - $4.5 $206,442 - $295,857	65,746 Added 72.25%	156,748 $577,000
Q3 2017 Nov 14, 2017	BUY	$1.69 - $4.33 $153,793 - $394,038	91,002	91,002 $394,000

Others Institutions Holding ARWR

# of Institutions

296

Shares Held

91.1M

Call Options Held

155K

Put Options Held

426K

View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $1.97B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

More about ARWR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account

Susquehanna International Group, LLP Arrowhead Pharmaceuticals, Inc. Transaction History